O	0	7	Genetic
O	8	16	variants
O	17	19	in
O	20	24	VEGF
O	25	32	pathway
O	33	38	genes
O	39	41	in
O	42	53	neoadjuvant
O	54	60	breast
O	61	67	cancer
O	68	76	patients
O	77	86	receiving
B-intervention	87	98	bevacizumab
O	98	99	:
O	100	107	Results
O	108	112	from
O	113	116	the
O	117	127	randomized
O	128	133	phase
O	134	137	III
O	138	149	GeparQuinto
O	150	155	study
O	155	156	.

O	157	164	Studies
O	165	174	assessing
O	175	178	the
O	179	185	effect
O	186	188	of
O	189	200	bevacizumab
O	201	202	(
O	202	205	BEV
O	205	206	)
O	207	209	on
O	210	216	breast
O	217	223	cancer
O	224	225	(
O	225	227	BC
O	227	228	)
O	229	236	outcome
O	237	241	have
O	242	247	shown
O	248	257	different
O	258	265	effects
O	266	268	on
O	269	280	progression
O	280	281	-
O	281	285	free
O	286	289	and
O	290	297	overall
O	298	306	survival
O	306	307	,
O	308	318	suggesting
O	319	323	that
O	324	325	a
O	326	334	subgroup
O	335	337	of
O	338	346	patients
O	347	350	may
O	351	358	benefit
O	359	363	from
O	364	368	this
O	369	378	treatment
O	378	379	.

O	380	393	Unfortunately
O	393	394	,
O	395	397	no
O	398	408	biomarkers
O	409	414	exist
O	415	417	to
O	418	426	identify
O	427	432	these
O	433	441	patients
O	441	442	.

O	443	447	Here
O	447	448	,
O	449	451	we
O	452	463	investigate
O	464	471	whether
O	472	478	single
O	479	489	nucleotide
O	490	503	polymorphisms
O	504	505	(
O	505	509	SNPs
O	509	510	)
O	511	513	in
O	514	518	VEGF
O	519	526	pathway
O	527	532	genes
O	533	542	correlate
O	543	547	with
O	548	560	pathological
O	561	569	complete
O	570	578	response
O	579	580	(
O	580	583	pCR
O	583	584	)
O	585	587	in
O	588	591	the
O	592	603	neoadjuvant
O	604	615	GeparQuinto
O	616	621	trial
O	621	622	.

B-eligibility	623	627	HER2
I-eligibility	627	628	-
I-eligibility	628	636	negative
I-eligibility	637	645	patients
O	646	650	were
O	651	661	randomized
O	662	666	into
O	667	676	treatment
O	677	681	arms
O	682	691	receiving
O	692	698	either
O	699	702	BEV
O	703	711	combined
O	712	716	with
O	717	725	standard
O	726	738	chemotherapy
O	739	741	or
B-control	742	754	chemotherapy
I-control	755	760	alone
O	760	761	.

O	762	764	In
O	765	766	a
O	767	770	pre
O	770	771	-
O	771	778	planned
O	779	788	biomarker
O	789	794	study
O	794	795	,
O	796	799	DNA
O	800	803	was
O	804	813	collected
O	814	818	from
B-intervention-participants	819	822	729
O	823	826	and
B-control-participants	827	830	724
O	831	839	patients
O	839	840	,
O	841	853	respectively
O	854	858	from
O	859	863	both
O	864	873	treatment
O	874	878	arms
O	878	879	,
O	880	883	and
O	884	893	genotyped
O	894	897	for
O	898	901	125
O	902	906	SNPs
O	906	907	.

O	908	916	Logistic
O	917	927	regression
O	928	936	assessed
O	937	948	interaction
O	949	956	between
O	957	967	individual
O	968	972	SNPs
O	973	976	and
O	977	981	both
O	982	991	treatment
O	992	996	arms
O	997	999	to
O	1000	1007	predict
O	1008	1011	pCR
O	1011	1012	.

O	1013	1017	Five
O	1018	1022	SNPs
O	1023	1026	may
O	1027	1029	be
O	1030	1040	associated
O	1041	1045	with
O	1046	1047	a
O	1048	1054	better
O	1055	1063	response
O	1064	1066	to
O	1067	1070	BEV
O	1070	1071	,
O	1072	1075	but
O	1076	1080	none
O	1081	1083	of
O	1084	1088	them
O	1089	1097	remained
O	1098	1109	significant
O	1110	1115	after
O	1116	1126	correction
O	1127	1130	for
O	1131	1139	multiple
O	1140	1147	testing
O	1147	1148	.

O	1149	1152	The
O	1153	1156	two
O	1157	1161	SNPs
O	1162	1166	most
O	1167	1175	strongly
O	1176	1186	associated
O	1186	1187	,
O	1188	1196	rs833058
O	1197	1200	and
O	1201	1209	rs699947
O	1209	1210	,
O	1211	1215	were
O	1216	1223	located
O	1224	1232	upstream
O	1233	1235	of
O	1236	1239	the
O	1240	1244	VEGF
O	1244	1245	-
O	1245	1246	A
O	1247	1255	promoter
O	1255	1256	.

O	1257	1261	Odds
O	1262	1268	ratios
O	1269	1272	for
O	1273	1276	the
B-outcome	1277	1287	homozygous
I-outcome	1288	1294	common
O	1294	1295	,
B-outcome	1296	1308	heterozygous
O	1309	1312	and
B-outcome	1313	1323	homozygous
I-outcome	1324	1328	rare
I-outcome	1329	1337	rs833058
I-outcome	1338	1347	genotypes
O	1348	1352	were
O	1353	1354	2
O	1354	1355	.
O	1355	1357	36
O	1358	1359	(
O	1359	1361	95
O	1361	1362	%
O	1363	1365	CI
O	1365	1366	,
O	1367	1368	1
O	1368	1369	.
O	1369	1371	49
O	1371	1372	-
O	1372	1373	3
O	1373	1374	.
O	1374	1376	75
O	1376	1377	)
O	1377	1378	,
O	1379	1380	1
O	1380	1381	.
O	1381	1383	20
O	1384	1385	(
O	1385	1387	95
O	1387	1388	%
O	1389	1391	CI
O	1391	1392	,
O	1393	1394	0
O	1394	1395	.
O	1395	1397	88
O	1397	1398	-
O	1398	1399	1
O	1399	1400	.
O	1400	1402	64
O	1402	1403	)
O	1404	1407	and
O	1408	1409	0
O	1409	1410	.
O	1410	1412	61
O	1413	1414	(
O	1414	1416	95
O	1416	1417	%
O	1418	1420	CI
O	1420	1421	,
O	1422	1423	0
O	1423	1424	.
O	1424	1426	34
O	1426	1427	-
O	1427	1428	1
O	1428	1429	.
O	1429	1431	12
O	1431	1432	)
O	1432	1433	.

O	1434	1441	Notably
O	1441	1442	,
B-outcome	1443	1447	some
I-outcome	1448	1452	SNPs
I-outcome	1453	1455	in
I-outcome	1456	1460	VEGF
I-outcome	1460	1461	-
I-outcome	1461	1462	A
O	1463	1472	exhibited
O	1473	1474	a
O	1475	1479	more
O	1480	1490	pronounced
O	1491	1497	effect
O	1498	1500	in
O	1501	1504	the
O	1505	1511	triple
O	1511	1512	-
O	1512	1520	negative
O	1521	1529	subgroup
O	1529	1530	.

O	1531	1538	Several
B-outcome	1539	1543	SNPs
I-outcome	1544	1546	in
I-outcome	1547	1551	VEGF
I-outcome	1551	1552	-
I-outcome	1552	1553	A
O	1554	1557	may
O	1558	1560	be
O	1561	1571	associated
O	1572	1576	with
O	1577	1585	improved
O	1586	1589	pCR
O	1590	1594	when
O	1595	1604	receiving
O	1605	1608	BEV
O	1609	1611	in
O	1612	1615	the
O	1616	1627	neoadjuvant
O	1628	1635	setting
O	1635	1636	.

O	1637	1645	Although
O	1646	1650	none
O	1651	1653	of
O	1654	1657	the
O	1658	1666	observed
O	1667	1674	effects
O	1675	1683	survived
O	1684	1694	correction
O	1695	1698	for
O	1699	1707	multiple
O	1708	1715	testing
O	1715	1716	,
O	1717	1720	our
O	1721	1733	observations
O	1734	1737	are
O	1738	1748	consistent
O	1749	1753	with
O	1754	1762	previous
O	1763	1770	studies
O	1771	1773	on
O	1774	1777	BEV
O	1778	1786	efficacy
O	1787	1789	in
O	1790	1792	BC
O	1792	1793	.

O	1794	1801	Further
O	1802	1810	research
O	1811	1813	is
O	1814	1823	warranted
O	1824	1826	to
O	1827	1834	clarify
O	1835	1838	the
O	1839	1849	predictive
O	1850	1855	value
O	1856	1858	of
O	1859	1864	these
O	1865	1872	markers
O	1872	1873	.
